HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 4 (April)

1. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis.
   Ophthalmology, 113(4): 684-94. [Abstract] [Full-text]
2. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.
   Ophthalmology, 113(4): 683.e1-8. [Abstract] [Full-text]
3. Assessing adult mortality in HIV-1-afflicted Zimbabwe (1998 -2003).
   Bull World Health Organ, 84(3): 189-97. [Abstract] [Full-text]
4. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis.
   Obstet Gynecol, 107(4): 807-12. [Abstract] [Full-text]
5. Assessment of trends in biological and behavioural surveillance data: is there any evidence of declining HIV prevalence or incidence in Malawi?
   Sex Transm Infect, 82: i9-13. [Abstract] [Full-text]
6. Behavioural data as an adjunct to HIV surveillance data.
   Sex Transm Infect, 82: i57-62. [Abstract] [Full-text]
7. Measuring trends in prevalence and incidence of HIV infection in countries with generalised epidemics.
   Sex Transm Infect, 82: i52-6. [Abstract] [Full-text]
8. Criteria for detecting and understanding changes in the risk of HIV infection at a national level in generalised epidemics.
   Sex Transm Infect, 82: i48-51. [Abstract] [Full-text]
9. HIV prevalence and trends from data in Zimbabwe, 1997-2004.
   Sex Transm Infect, 82: i42-7. [Abstract] [Full-text]
10. Trends in antenatal HIV prevalence in urban Uganda associated with uptake of preventive sexual behaviour.
    Sex Transm Infect, 82: i36-41. [Abstract] [Full-text]
11. HIV/AIDS in Ethiopia: where is the epidemic heading?
    Sex Transm Infect, 82: i32-5. [Abstract] [Full-text]
12. Current trends in Rwanda's HIV/AIDS epidemic.
    Sex Transm Infect, 82: i27-31. [Abstract] [Full-text]
13. Evidence for population level declines in adult HIV prevalence in Kenya.
    Sex Transm Infect, 82: i21-6. [Abstract] [Full-text]
14. Understanding the reasons for decline of HIV prevalence in Haiti.
    Sex Transm Infect, 82: i14-20. [Abstract] [Full-text]
15. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti.
    Sex Transm Infect, 82: i1-8. [Abstract] [Full-text]
16. Cooperativity between Rad51 and C/EBP family transcription factors modulates basal and Tat-induced activation of the HIV-1 LTR in astrocytes.
    J Cell Physiol, 207(3): 605-13. [Abstract] [Full-text]
17. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana.
    J Med Microbiol, 55: 593-7. [Abstract] [Full-text]
18. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
    Br J Cancer, 94(7): 1000-6. [Abstract] [Full-text]
19. Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection.
    J Gen Virol, 87: 1311-20. [Abstract] [Full-text]
20. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    J Gen Virol, 87: 1303-9. [Abstract] [Full-text]
21. In primary human monocyte-derived macrophages exposed to Human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake?
    J Gen Virol, 87: 1295-302. [Abstract] [Full-text]
22. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
    J Gen Virol, 87: 1285-94. [Abstract] [Full-text]
23. Tubulin-mediated binding of human immunodeficiency virus-1 Tat to the cytoskeleton causes proteasomal-dependent degradation of microtubule-associated protein 2 and neuronal damage.
    J Neurosci, 26(15): 4054-62. [Abstract] [Full-text]
24. Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation.
    J Virol, 80(9): 4570-9. [Abstract] [Full-text]
25. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
    J Virol, 80(9): 4440-6. [Abstract] [Full-text]
26. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells.
    J Virol, 80(9): 4388-95. [Abstract] [Full-text]
27. Advancement of global health: key messages from the Disease Control Priorities Project.
    Lancet, 367(9517): 1193-208. [Abstract] [Full-text]
28. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study.
    Lancet, 367(9517): 1164-72. [Abstract] [Full-text]
29. Molecular biology of squamous cell carcinoma of the anus.
    Br J Surg, 93(5): 531-8. [Abstract] [Full-text]
30. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
    J Infect Dis, 193(10): 1437-40. [Abstract] [Full-text]
31. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi.
    Bull World Health Organ, 84(4): 320-6. [Abstract] [Full-text]
32. Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia.
    Bull World Health Organ, 84(4): 269-75. [Abstract] [Full-text]
33. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy.
    Brain, 129: 1330-8. [Abstract] [Full-text]
34. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
    Lancet, 367(9519): 1335-42. [Abstract] [Full-text]
35. Role of parametric resonance in virological failure during HIV treatment interruption therapy.
    Lancet, 367(9518): 1285-9. [Abstract] [Full-text]
36. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
    Lancet, 367(9518): 1256-61. [Abstract] [Full-text]
37. Immunological recovery and antiretroviral therapy in HIV-1 infection.
    Lancet Infect Dis, 6(5): 280-7. [Abstract] [Full-text]
38. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics.
    Am J Epidemiol, 163(9): 860-9. [Abstract] [Full-text]
39. The effects of religious affiliation on sexual initiation and condom use in Zambia.
    J Adolesc Health, 38(5): 550-5. [Abstract] [Full-text]
40. Specific recognition of HIV TAR RNA by the dsRNA binding domains (dsRBD1-dsRBD2) of PKR.
    J Mol Biol, 358(2): 430-42. [Abstract] [Full-text]
41. Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care Settings.
    Sex Transm Dis, 33(5): 329-33. [Abstract] [Full-text]
42. Human T lymphotropic virus type I/II infection: prevalence and risk factors in individuals testing for HIV in counseling centers from Southern Brazil.
    Sex Transm Dis, 33(5): 302-6. [Abstract] [Full-text]
43. A systematic review of HIV partner counseling and referral services: client and provider attitudes, preferences, practices, and experiences.
    Sex Transm Dis, 33(5): 320-8. [Abstract] [Full-text]
44. Adapting efficacious interventions: advancing translational research in HIV prevention.
    Eval Health Prof, 29(2): 162-94. [Abstract] [Full-text]
45. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.
    J Mol Biol, 358(5): 1191-9. [Abstract] [Full-text]
46. Parent-child communication: a model for Hispanics on HIV prevention.
    J Community Health Nurs, 23(2): 81-94. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.